Important changes in treatment. New rules apply from July

• From July 1, 2025, patients with BRCA-related cancers can undergo genetic testing on an outpatient basis - without the need for hospitalization
• The change was introduced at the request of the Ministry of Health, in response to the demands of experts and patient organizations.
• BRCA mutations are important not only in breast and ovarian cancer, but also in pancreatic, fallopian tube, peritoneal and prostate cancer.

Molecular blood tests are performed to select the appropriate treatment regimen for an oncology patient. The patient comes to the hospital only for a blood draw and returns home the same day.

As the Ministry of Health emphasizes in a press release, BRCA mutations are important not only in the case of breast or ovarian cancer, but also pancreatic, fallopian tube, peritoneal and prostate cancer.

- These studies will improve the qualification of patients for appropriate drug programs, regardless of whether the patient will ultimately be included in them - explains the ministry.

The new regulations also expand access to genetic diagnostics for patients with:

• cancer of the gallbladder and bile ducts,
• renal pelvis, ureter and other parts of the urinary tract.

Modern research "on the National Health Fund"

The reimbursement covers modern genetic tests performed using advanced DNA and RNA sequencing techniques (NGS). The financing applies to situations where diagnostics are necessary to start targeted oncological treatment.

- Reimbursement of outpatient genetic tests and the extension of the cancer catalogue in this respect is another step towards facilitating access to innovative diagnostics and modern treatment for all oncological patients - sums up the Ministry of Health.

Copyrighted material - reprint rules are specified in the regulations .